BayMedica - Rare Cannabinoid Ingredients
InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. BayMedica has engineered bioidentical cannabinoids with high purity and consistency, and free of THC.
We know cannabinoids in depth.
Call us cannabinoid nerds. Our team of scientists have a depth of experience in cannabinoid biosynthesis, chemical synthesis and enzymatic biotransformation.
Our subsidiary, BayMedica, has been able to reliably manufacture rare, minor cannabinoids that are bioidentical. This means that our cannabinoids have an identical molecular structure to the cannabinoids found in the Cannabis plant. BayMedica has manufactured these rare cannabinoids at commercial scale as core ingredients for your health and wellness products. BayMedica’s rare cannabinoid ingredients include cannabichromene (CBC), tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and ultra-rare cannabinoid cannabicitran (CBTC), available in any quantity needed.
Rare Cannabinoid Ingredients for B2B Purchase
Cannabichromene (CBC) is non-intoxicating, non-psychoactive cannabinoid that is believed to function by binding the CB2 receptor as well as the vanilloid receptor 1 (TRPV1) and transient receptor potential ankyrin 1 (TRPA1). The result of engaging these receptors is increased levels of natural endocannabinoids that are known to have positive effects on many body systems.
Tetrahydrocannabivarin (THCV) is a minor cannabinoid and recognized as non-intoxicating. d9-THCV has been shown to act as an antagonist of CB1 receptors of the endocannabinoid system as well as other endogenous receptors including GPR55 and TRPV1. d9-THCV has been the subject of much clinical and nonclinical research into its physiological effects, with most of the research focused on studying its appetite suppressive effects.
Cannabidivarin (CBDV), is a non-psychoactive compound found in C. sativa, but unlike cannabidiol (CBD), CBDV is produced in very small amounts in hemp. CBDV has been shown to act through binding of various receptors including the ankryin-type receptor TRPA1 and vanilloid-type, TRPV1 and TRPV2 receptors. Like other CB2 agonists, CBDV is believed to produce a number of positive effects by engaging the endocannabinoid system.
Cannabicitran (CBT) is an ultra-rare cannabinoid found in the cannabis plant and is recognized as a non-intoxicating cannabinoid. CBT was discovered and isolated from Lebanese Cannabis sativa in 1974.
Purity and quality you can trust
While many scientists may be able to reproduce a cannabinoid in the lab, very few can take it to large scale production. We can and we have. We produce rare, minor cannabinoids with the consistent high quality and purity needed for the health and wellness industry. Our cannabinoids are made via “pharmaceutical-quality” techniques, are lab tested, and third-party certified. Our cannabinoids can be combined in precise ratios to produce Defined Spectrum™ formulations with putative synergistic, so-called, “entourage” or “potentiation” effects.
Move over CBD – Rare cannabinoids are the next big thing.
Beyond THC and CBD, there are more than a hundred rare cannabinoids that have unique characteristics that may have different physiological effects. Research suggests that these rare, minor cannabinoids may have more beneficial effects than THC and CBD for certain applications. Until now, you couldn’t readily obtain these rare, minor cannabinoids because of their extremely low levels in the cannabis plant, making them impractical and expensive to extract and separate from unwanted components like THC. We have pioneered the application of pharmaceutical methods like chemical synthesis and biosynthesis to produce these valuable minor cannabinoids. Interested in learning more about the scientific research of rare cannabinoids?
BayMedica's Cannabinoid Synthesis
BayMedica, has created an efficient, patent-pending, biological factory by taking the blueprints for cannabinoid biosynthesis from the cannabis plant and engineering it into ultra-efficient brewer’s yeast. BayMedica utilizes its expertise in synthetic chemistry to complement its biosynthesis platform. BayMedica’s platform has been able to produce highly pure bioidentical cannabinoids at large scale.
The BayMedica platform provides an alternative solution by engineering common yeast to convert sugar into cannabinoids, including common and rare natural varieties, as well as novel cannabinoid analogs of pharmaceutical interest. BayMedica also leverages its experience in synthetic chemistry where applicable. Its cannabinoids have a wide variety of applications in the pharmaceutical, cosmetic, consumer and animal health industries.
Consistent & Pure
- Our products are made through a consistent, reproducible process that results in greater purity and consistency than attained by extracting plant material.
- Our proprietary platform enables the benefits of cannabis without touching the plant.
Rare & Analog Cannabinoids
- We can produce common and rare cannabinoid compounds as well as analog compounds not present in the plant.
Scalable & Cost Effective
- The BayMedica method allows for scalable, cost-effective cannabinoid production.
- We have been able to reliably manufacture rare cannabinoids that are bioidentical to those found in the plant. Our cannabinoids have an identical molecular structure.
Market Specific Solutions
- BayMedica cannabinoids can be tailored for pharmaceutical, nutraceutical, cosmetic, consumer and animal health markets.